SEC Form 4 · accession 0001193125-26-295148
Shattuck Labs, Inc. · STTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arundathy N. Pandite
Officer — Chief Medical Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 8:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001680367
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 30, 2026 | S | 30,000 | $7.01 | D | 136,219 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.62 to $7.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.